Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01. [electronic resource]
Producer: 20190920Description: 1-10 p. digitalISSN:- 1873-4995
- Adjuvants, Immunologic -- administration & dosage
- Animals
- Female
- Glycolipids -- administration & dosage
- Imidazoles -- administration & dosage
- Lipids -- chemistry
- Liposomes -- chemistry
- Mice, Inbred BALB C
- Quaternary Ammonium Compounds -- chemistry
- Toll-Like Receptor 7 -- agonists
- Vaccines -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.